An orexin agonist restores wakefulness in narcolepsy type 1

Design

two phase 3, randomised, placebo-controlled trials, 12 weeks

Population

273 participants aged 16 to 70 with narcolepsy type 1

Primary outcome

change in mean sleep latency on the Maintenance of Wakefulness Test at week 12

Effect

+14.3 to +19.8 minutes with oveporexton vs -0.4 to -0.8 with placebo

Narcolepsy type 1 is caused by loss of orexin-producing neurons, so an orexin receptor agonist replaces what is missing rather than stimulating around it. Two phase 3 trials, First Light and Radiant Light, randomised 273 people aged 16 to 70 to twice-daily oral oveporexton or placebo for 12 weeks.

Mean sleep latency on the Maintenance of Wakefulness Test rose by 14.3 to 19.8 minutes across the active arms, against a fall of 0.4 to 0.8 minutes on placebo. On a test that runs to 40 minutes and where 20 is normal, that is a shift from pathological to near-normal wakefulness. Epworth scores fell 9.7 to 11.8 points against 1.5 to 1.7 on placebo, and weekly cataplexy fell by a median 79% to 89% against 28% to 39%.

Adverse events occurred in 86% to 89% on the drug against 43% to 54% on placebo, most commonly increased urinary frequency and transient insomnia, both affecting a majority of treated participants. For a condition managed for decades with stimulants and sodium oxybate, effect sizes of this magnitude are unusual. Twelve weeks is short, the trials were manufacturer-funded, and the drug is not yet licensed.

• Effect size is in the range that changes a diagnostic category, not a symptom score.
• Increased urinary frequency affected most treated participants - a predictable question if it reaches clinic.
• Type 1 narcolepsy only; nothing here applies to type 2 or to idiopathic hypersomnia.
• Twelve weeks of data; durability and long-term safety are unknown.
• Worth knowing for the patient with cataplexy who has failed existing options.

Why it matters

It is the first treatment aimed at the actual defect in narcolepsy type 1 rather than at its symptoms.

Don't overread it

Phase 3 over 12 weeks, manufacturer-funded, not licensed - durability and rare harms are both unknown.

The statistics, in plain English

A change of 14 to 20 minutes on a 40-minute test, from a baseline of pathological sleepiness, is a large absolute effect rather than a statistically detectable small one - the distinction that usually matters most when reading a trial. The cataplexy reduction is reported as a median percentage change, which is less informative than absolute attack rates, and the placebo arms improved by 28% to 39% on that same measure.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.